Biomea Fusion, Inc.

Contributing Author

Recent Articles by Biomea Fusion, Inc.

Jun-23	Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) BMEA GlobeNewswire
Jun-18	Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates BMEA GlobeNewswire
Jun-17	Biomea Fusion Announces Pricing of Public Offering of Securities BMEA GlobeNewswire
Jun-17	Biomea Fusion Announces Proposed Public Offering of Securities BMEA GlobeNewswire
Jun-13	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 BMEA GlobeNewswire
May-14	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia BMEA GlobeNewswire
May-05	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire